

February 2022

Dear eye care professional,

Thank you for your participation in the Versant Health panel of eye care professionals. As part of our ongoing commitment to open lines of communication, we are sending this letter to inform you of updates and additional medical policies recently approved by the Versant Health Medical Policy Council.

The following policies have been added or updated with effective dates as noted.

Policy Number and Name	Criteria Changes	Effective Date
1300 Cataract Surgery	 Updated criteria for MIGS combination procedures Adds 2 procedures, with criteria, for ab-interno insertion of aqueous drainage devices Adds 2 newly CMS released CPT codes 	4/1/2022
1309 Medically Necessary Contact Lenses	 Removed requirements for greater than 2.5 diopters of keratometric astigmatism. Reorganized policy by CPT codes; deleted diagnoses codes within body of policy. 	4/1/2022
1310 Refraction	Annual review; no criteria changes	2/1/2022
1311 Adult Strabismus Surgery	Annual review; no criteria changes	4/1/2022
1312 Amniotic Membrane	No written criteria changes.Added CPT codes 65781 and 65782	4/1/2022
1313 Retinal Angiography	Annual review; no criteria changes	4/1/2022
1314 Corneal Topography	Annual review; no criteria changes	4/1/2022
1315 Keratoplasty	Annual review; no criteria changes	4/1/2022
1317 Vascular Endothelial Growth Factor Inhibitors (Anti- VEGF)	 Policy renamed to Vascular Endothelial Growth Factor Inhibitors (Anti-VEGF). Added two drugs with criteria, Byooviz and Susvimo. Removed corticosteroids and Jetrea ocriplasmin to separate policies. (Corticosteroid drugs remain on 1317 policy until 7/1/2022.) 	7/1/2022
1327 Glaucoma surgery	 Aligned policy with 1300 Cataract Surgery for MIGS procedures criteria. Added CMS released codes 66989 and 66991. Removed CMS deleted code 0671T, add CMS released code 0671T. 	4/1/2022

1335 Extended Ophthalmoscopy	Administrative correction to list of coding modifiers	2/1/2022
1336 Telemedicine	Added 17 new CPT codes per CMS guidance	7/1/2022
1343 Durysta	Annual review; no criteria changes	2/1/2022
1346 Corticosteroid Implants	 New policy extracts corticosteroid drugs from 1317, Anti-VEGF policy. Corticosteroid drugs remain on policy 1317 until 7/1/2022. Adds drug Dextenza with indications and criteria 	7/1/2022
1347 Jetrea	 Policy extracts Jetrea ocriplasmin from 1317 policy with no criteria change for the procedure. Drug use and policy retires on 4/1/2022; drug is no longer available in the U.S. 	4/1/2022

Versant Health, which brings you the Superior Vision network and the Davis Vision network, maintains and provides access to our policies which can be accessed via the Eye Care Professional Portal located at **ecp.versanthealth.com**. The medical policies can be found by selecting "Health Plans" and then "Medical Management" from the left side navigation bar on the portal home page. Additionally, the most current Prior Authorization list can be found in the same location.

We greatly appreciate the professional services which you render to our members. Thank you for being a part of the Versant Health network of eye care professionals.

Sincerely,

Mark C. Ruchman, MD Chief Medical Officer



